Salarius Pharmaceuticals, Inc.
SLRX
$0.698
-$0.0348-4.75%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 51.10% | -30.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 47.91% | -31.41% | |||
| Operating Income | -47.91% | 31.41% | |||
| Income Before Tax | -50.59% | 31.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -50.59% | 31.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -50.59% | 31.75% | |||
| EBIT | -47.91% | 31.41% | |||
| EBITDA | -47.96% | 31.44% | |||
| EPS Basic | -33.61% | 68.03% | |||
| Normalized Basic EPS | -33.61% | 68.03% | |||
| EPS Diluted | -33.61% | 68.03% | |||
| Normalized Diluted EPS | -33.61% | 68.03% | |||
| Average Basic Shares Outstanding | 12.70% | 113.51% | |||
| Average Diluted Shares Outstanding | 12.70% | 113.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||